Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Liminatus Pharma ( (LIMN) ) has provided an announcement.
On August 22, 2025, Liminatus Pharma, Inc. received a notice from Nasdaq indicating non-compliance with a listing rule due to a delay in filing its Quarterly Report for the period ended June 30, 2025. The notice does not immediately affect the trading of its stock, and the company has until October 21, 2025, to submit a compliance plan. If accepted, Nasdaq may grant an extension until February 16, 2026. Liminatus Pharma is working to complete the filing and intends to submit it promptly.
More about Liminatus Pharma
Average Trading Volume: 1,240,728
Technical Sentiment Signal: Sell
Current Market Cap: $92.29M
For detailed information about LIMN stock, go to TipRanks’ Stock Analysis page.